on DIAGNOSTIC MEDICAL (EPA:ALDMS)
DMS Group's Annual Performance and Results for 2025
DMS Group recorded organic growth of 8.5% in 2025, with revenue reaching €50 million. EBITDA increased by 69% to €4.6 million, reflecting improved margins and effective cost management.
This performance is attributed to international expansion, particularly in North America with 71% growth, and to partnerships in mobile radiology. Conversely, Europe experienced an 8% decline in market share.
With positive results and a solid financial boost, notably thanks to a €6.9 million fundraising round, DMS plans to outperform the medical imaging market despite geo-economic uncertainties.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DIAGNOSTIC MEDICAL news